312 related articles for article (PubMed ID: 15710258)
1. [Thalidomide: mechanisms of action and new insights in hematology].
Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
[TBL] [Abstract][Full Text] [Related]
2. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
3. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
4. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
5. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
6. Potential new therapeutics for Waldenstrom's macroglobulinemia.
Zeldis JB; Schafer PH; Bennett BL; Mercurio F; Stirling DI
Semin Oncol; 2003 Apr; 30(2):275-81. PubMed ID: 12720152
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of thalidomide in hematologic disorders: a review.
Xu M; Hou Y; Sheng L; Peng J
Front Med; 2013 Sep; 7(3):290-300. PubMed ID: 23856973
[TBL] [Abstract][Full Text] [Related]
8. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Vallet S; Witzens-Harig M; Jaeger D; Podar K
Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory drugs in myelodysplastic syndromes.
Galili N; Raza A
Expert Opin Investig Drugs; 2006 Jul; 15(7):805-13. PubMed ID: 16787143
[TBL] [Abstract][Full Text] [Related]
10. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
Jiménez Lozano I; Juárez Jiménez JC
Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory drugs.
Crane E; List A
Cancer Invest; 2005; 23(7):625-34. PubMed ID: 16305990
[TBL] [Abstract][Full Text] [Related]
12. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Schafer PH
Expert Opin Pharmacother; 2012 Jul; 13(10):1541-2. PubMed ID: 22646699
[No Abstract] [Full Text] [Related]
13. The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Pan B; Lentzsch S
Pharmacol Ther; 2012 Oct; 136(1):56-68. PubMed ID: 22796518
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Wiernik PH
Curr Treat Options Oncol; 2009 Apr; 10(1-2):1-15. PubMed ID: 19016330
[TBL] [Abstract][Full Text] [Related]
15. Recent advances of IMiDs in cancer therapy.
Li S; Gill N; Lentzsch S
Curr Opin Oncol; 2010 Nov; 22(6):579-85. PubMed ID: 20689431
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide: present and future in multiple myeloma.
Hussein MA
Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
[TBL] [Abstract][Full Text] [Related]
17. Current status of thalidomide in the treatment of cancer.
Rajkumar SV
Oncology (Williston Park); 2001 Jul; 15(7):867-74; discussion 877-9. PubMed ID: 11499688
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide in multiple myeloma.
Rajkumar SV
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):11-6. PubMed ID: 11204667
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
20. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Rajkumar SV; Witzig TE
Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
